Global Cancer Statistics 2022: the trends projection analysis BS Chhikara, K Parang Chemical Biology Letters 10 (1), 451-451, 2023 | 355 | 2023 |
Self-assembly of peptides to nanostructures D Mandal, AN Shirazi, K Parang Organic & biomolecular chemistry 12 (22), 3544-3561, 2014 | 316 | 2014 |
Mechanism-based design of a protein kinase inhibitor K Parang, JH Till, AJ Ablooglu, RA Kohanski, SR Hubbard, PA Cole Nature structural biology 8 (1), 37-41, 2001 | 289 | 2001 |
A global review on short peptides: frontiers and perspectives V Apostolopoulos, J Bojarska, TT Chai, S Elnagdy, K Kaczmarek, ... Molecules 26 (2), 430, 2021 | 264 | 2021 |
Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity BJ Fowler, BD Gelfand, Y Kim, N Kerur, V Tarallo, Y Hirano, S Amarnath, ... Science 346 (6212), 1000-1003, 2014 | 234 | 2014 |
Protein pyrophosphorylation by inositol pyrophosphates is a posttranslational event R Bhandari, A Saiardi, Y Ahmadibeni, AM Snowman, AC Resnick, ... Proceedings of the National Academy of Sciences 104 (39), 15305-15310, 2007 | 232 | 2007 |
Cell‐penetrating homochiral cyclic peptides as nuclear‐targeting molecular transporters D Mandal, A Nasrolahi Shirazi, K Parang Angewandte Chemie-International Edition 50 (41), 9633, 2011 | 217 | 2011 |
Novel Approaches for Designing 5'-O-Ester Prodrugs of 3'-Azido-2'3'-Dideoxythymidine (AZT) K Parang, LI Wiebe, EE Knaus Current medicinal chemistry 7 (10), 995-1039, 2000 | 205 | 2000 |
Impairment of TrkB-PSD-95 signaling in Angelman syndrome C Cao, MS Rioult-Pedotti, P Migani, CJ Yu, R Tiwari, K Parang, ... PLoS biology 11 (2), e1001478, 2013 | 183 | 2013 |
Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease T Force, K Kuida, M Namchuk, K Parang, JM Kyriakis Circulation 109 (10), 1196-1205, 2004 | 162 | 2004 |
Current targets for anticancer drug discovery NH Nam, K Parang Current drug targets 4 (2), 159-179, 2003 | 150 | 2003 |
Designing bisubstrate analog inhibitors for protein kinases K Parang, PA Cole Pharmacology & therapeutics 93 (2-3), 145-157, 2002 | 147 | 2002 |
Development of cytarabine prodrugs and delivery systems for leukemia treatment BS Chhikara, K Parang Expert opinion on drug delivery 7 (12), 1399-1414, 2010 | 132 | 2010 |
Design and biological evaluation of cell-penetrating peptide–doxorubicin conjugates as prodrugs A Nasrolahi Shirazi, R Tiwari, BS Chhikara, D Mandal, K Parang Molecular pharmaceutics 10 (2), 488-499, 2013 | 131 | 2013 |
Synthesis of 3-phenylpyrazolopyrimidine-1, 2, 3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities A Kumar, I Ahmad, BS Chhikara, R Tiwari, D Mandal, K Parang Bioorganic & medicinal chemistry letters 21 (5), 1342-1346, 2011 | 127 | 2011 |
Cyclic cell-penetrating peptides as efficient intracellular drug delivery tools SE Park, MI Sajid, K Parang, RK Tiwari Molecular pharmaceutics 16 (9), 3727-3743, 2019 | 121 | 2019 |
Fatty acyl amide derivatives of doxorubicin: Synthesis and in vitro anticancer activities BS Chhikara, NS Jean, D Mandal, A Kumar, K Parang European journal of medicinal chemistry 46 (6), 2037-2042, 2011 | 103 | 2011 |
Determination of the substrate-docking site of protein tyrosine kinase C-terminal Src kinase S Lee, X Lin, NH Nam, K Parang, G Sun Proceedings of the National Academy of Sciences 100 (25), 14707-14712, 2003 | 102 | 2003 |
A review (research and patents) on jasmonic acid and its derivatives A Ghasemi Pirbalouti, SE Sajjadi, K Parang Archiv der Pharmazie 347 (4), 229-239, 2014 | 101 | 2014 |
Synthesis, anticancer activities, and cellular uptake studies of lipophilic derivatives of doxorubicin succinate BS Chhikara, D Mandal, K Parang Journal of medicinal chemistry 55 (4), 1500-1510, 2012 | 95 | 2012 |